US EditionLifeTech Scientific Corporation Announces 2025 Interim Results: Core Business Demonstrated Resilience, Domestic and Overseas Sales Both Increased
- LifeTech Scientific Corporation achieved revenue of approximately RMB676.7 million during the Reporting Period, representing a year-on-year increase of approximately 3.7%.
- The gross profit was approximately RMB497.8 million, and net profit attributable to owners was approximately RMB238.5 million, marking a year-on-year increase of approximately 2.1%.
- The Group's overseas sales grew by approximately 8.0% year-on-year, driven by proactive expansion and effective marketing strategies.
- The Group's strategy focused on addressing unmet clinical needs worldwide, with China's mainland as its largest market accounting for approximately 74.1% of total revenue.
Insights by Ground AI
Does this summary seem wrong?
34 Articles
34 Articles
The Berkshire Eagle+33 Reposted by 33 other sources
LifeTech Scientific Corporation Announces 2025 Interim Results: Core Business Demonstrated Resilience, Domestic and Overseas Sales Both Increased
HONG KONG, Aug. 29, 2025 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today…
Coverage Details
Total News Sources34
Leaning Left4Leaning Right3Center9Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 25%
C 56%
R 19%
Factuality
To view factuality data please Upgrade to Premium
